COVID-19 Antibody Therapy was approved by the United States Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA) declaration for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients who qualify for treatment. This therapy has been proven to keep patients from worsening to the point of requiring hospitalization due to COVID-19 by 87%.
This therapy is not a substitute for a COVID-19 vaccine.